Dear Self-Directed Accredited Investor,

It may sound too good to be true, but every word of this research headline is VERY factual.

And after the EXTREME stock market parabolic melt-ups and the predictable parabolic melt-downs of our favorite AI Data Center memory and optical networking stocks, seemingly every 60 days...

. . . It's a great time to make sure you are aware of the most amazing investment opportunity I have seen in my 40+ years on Wall Street/Equity Research/Wealth Management career — for your personal account or your IRA/Roth IRA . . . and I need to make sure you understand this deal will be closed forever in the next few weeks.

Of course, your first question should be "Toby--how is it possible that you can forecast a 10-20X return on any investment?" And my answer is simple: I have never seen ANY investment opportunity like BreezLyte LLC and their unique, CDC-licensed, and USA-patent-pending medical-grade N95 mask manufacturing technology.

Please stay with me—the next 5 minutes could significantly improve your family's wealth.

First off, unless you work in the healthcare, manufacturing, or construction industries, your experience with an N95 Respirator Mask is probably from the COVID-19 pandemic or a hospital visit. Remember this?

These masks were A) hard to breathe through, B) not 100% safe from microscopic germs, and C) ALL imported from China.

On the other hand, here is the 100% patented and ONLY NIOSH/CDC certified BreezLyte N95 Respirator made in America in comparison--super easy to breathe through and made in Northern California on the world's first patented 100% robotic N95 mask manufacturing assembly line that runs 6 days a week 24 hours a day and makes 300,000 masks every month PER line--soon 30 million N95 masks per month right here in America--and WITHOUT the 50%+ tariffs charged in 2026 to import poorly made N95 masks or mask material from China!

Section 301 Tariffs (The Strategic Increase)

Following the Office of the U.S. Trade Representative's (USTR) statutory four-year review, the Section 301 penalty tariffs on Chinese medical face masks and respirators were significantly escalated to help level the playing field for domestic manufacturing:

Late 2024–2025 Rate: 25%
Current 2026 Rate: 50% (effective January 1, 2026)

And guess what--BreezLyte LLC:

1) Makes the ONLY N95 respirator NIOSH-certified and licensed to be made in the United States
2) America goes through over 1 billion single-use N95 masks every year--and growing @8% annually.
3) EACH robotic BreezLyte production line can produce 300,000 N95 masks per month
4) And purchased in bulk, the BreezLyte N95 masks are @30% less expensive than
5) Inferior Chinese-made N95 masks distributed in America

Total Estimated Impact

When combining the current Section 301 penalty rate with standard baseline duties, the effective import tariff on Chinese N95 masks is 57% of the item's declared customs value.

Really Key Point: BreezLyte's products address HUGE global market demand growing from $10B in ’24 to $20B in 2030

Decoupling from China, creating a supply shortage, with the Section 301 import tariff rate increased from 25% to 50% on N95 masks
Return to pre-pandemic single-use protocols, i.e., the standard “one patient one mask” healthcare protocols, significantly increases N95 volume demand in regular usage
Tens of millions of expired national and state strategic stockpiles REQUIRE immediate replenishment

Current Post-Pandemic Structured Market Split

Following the massive scale-up of healthcare stockpiles and shifting global supply baselines, recent market share data breaks down the US commercial N95 respirator market revenue roughly as follows:

Construction Sector: Holds about 30% to 31% of the total N95 market share. Continuous exposure to dust, silica particles, and concrete masonry requires strict compliance with OSHA respiratory protection protocols.
Manufacturing Sector: Drives another 25% to 28% of consistent demand, spanning automotive assembly, chemical processing, metal work, and electronics production.
Combined Industrial Total: Together, construction and manufacturing account for roughly 55%-60% of day-to-day N95 market consumption.

The remaining ~40% of the market is split among institutional healthcare systems (which maintain highly elevated readiness and active stockpiling protocols relative to pre-2020 baselines), government/defense agencies, and individual household automation-driven use.

Personal Protective Equipment (PPE) Made in America

AI and cutting-edge manufacturer
Producing the PPE onshore at globally competitive prices

AIR 2020 – BreezLyte’s Premier Gold Standard N95 Respirator

Patent-pending design with input from medical professionals
Very low breathing resistance
Very high filtration efficiency
Better seal & greater comfort

“The breathability of these respirators is fantastic! It fits tightly to the skin around its entire perimeter. While trying these respirators out, I sat down to relax, watching the news on TV, and forgot I even had it on, which I could never do with other N95 respirators. ”
—Gary Peck, MD
Dermatological Oncologist, National Cancer Institute; Discoverer of Accutane

Decoupling from China creating supply shortage

Return to pre-pandemic single-use protocols, increasing volume in regular usage
Expired national and state strategic stockpiles requiring replenishment

BreezLyte's Incomparable Competitive Advantage

Made in USA; other manufacturers, including 3M, face significant impact from tariffs
Compared to competition: More comfort, higher filtration, better breathability
Custom design; US patent application no. 18/674,124
Cheaper with higher margins
US regulatory reorganization has raised barriers for new entrants

The World Class Team Behind BreezLyte

BreezLyte management has decades of industry experience. The team’s previous roles include leadership positions in the personal protective equipment, pharmaceutical, and high-tech industries.

Douglas Pahel, PhD, President and CTO
Long history of Project Management, Research and Development, and Global Procurement
Joe Jennings, Head of Compliance
In charge of respirator production for Honeywell during the pandemic
Dale Christman, Head of Operations
Long history in the Semiconductor and Manufacturing Industries
Jeremy Levin, Head of Sales
Former Head of US Sales for Zhende, one of the largest PPE manufacturers in the world domiciled in China

BreezLyte is Entering a MASSIVE Growth Inflection Point

Current facility can support >30 million respirators/month
Future products will include surgical N95 respirators, biodegradable respirators, and surgical gowns
GPOs (Group Purchasing Organizations) are the standard channels for N95 sales. BreezLyte GPO agreements to date:
- K1 Medical – 2500 Members – February 2026
- Medigroup – 40000 Members – April 2026
- Marathon Medical – Government Sales – April 2026
- Eirionyx Global Medical Alliance – 30,000 members April 2026
- PLUS an additional national and regional 15 GPO sales agreements WILL be added as capacity ramps to 30 million N95 masks produced MONTHLY
- BL is also in serious discussions regarding the production of a private label with one major N95 distribution entity to be named shortly
Really Key Point: As of June 15, BL has been approved and entered Henry Schein’s, McKesson’s, and Owens & Minor’s NATIONAL distribution networks representing $>220 billion in annual healthcare product sales

Organized as an LLC that distributes annual profits to investors pro rata

‘Clean’ Cap Table: Majority of investors are doctor groups & their affiliated investment funds
BreezLyte’s unique company structure distributes annual profits to investors while at the same time providing additional equity upside through a future liquidity event, i.e., the sale of the company to one of the major N95 GPOs or national N95 distributors

The Investment Opportunity

Currently raising $2.5M equity round to support production and sales ramp-up
Offering Preferred A2 Units at $0.36 per unit, closing
Delivers passive LLC income generation + equity upside
Profits are first distributed to Preferred A Unit holders until their entire investment amount is returned. Thereafter, Preferred Units convert to Common, and net profit is distributed pro rata
Expected exit via sale to a strategic buyer at significant further upside

Your Deadline To Invest in BreezLyte Capital LLC is Near--August 15

Investment Structure & Terms

BreezLyte is raising a $2.5M equity round to support production scale-up.

Offering: Preferred A2 Units at $0.36 per unit.
Minimum Investment: $25,000.
Key Incentive to Act NOW!: New Investors get a BONUS 20% warrant coverage (at $0.03 exercise price) for current subscribers/clients, lowering your effective pre-money valuation to $25M that ADDS 20% to your total investment return on investment.

Sample Investment Allocations

Investment Amount	Preferred A Units	Common Unit Warrants ($0.03/unit)
$100,000	277,777	55,555
$50,000	138,888	27,777
$25,000 (Minimum)	69,444	13,888

Distribution & Tax Considerations

As an LLC, net profits are distributed pro-rata to investors. Initial distributions are allocated to Preferred A Unit holders until the principal investment is returned.

Distribution & Tax Considerations

As an LLC, net profits are distributed pro-rata to investors. Initial distributions are allocated to Preferred A Unit holders until the principal investment is returned.

Your NEXT STEPS: Here are your subscription documents

Please visit https://docuseal.com/d/1hHNEtvzePCQL2 to complete the Subscription Agreement.

For IRA Investors, Madison Trust has performed extensive due diligence on my BreezLyte Capital LLC SPV and accepts IRA and Roth IRA funds for transfer to their IRA Trust account to purchase BreezLyte LLC units.

Here is the custom application link to open new Madison Trust IRA accounts.

Custom App Link: https://clientportal.madisontrust.com/enroll-client?Reference=Ian%20Robertson&PromoCode=100SignUp&ReferralSource=Transformity%20Research

The link will waive a new client's $50 application fee and their first investment fee of $75.

Note: Clients who are already with Madison Trust only need their investment documents so MT can process them and countersign.

Your next step: secure your allocation in my SPV, BreezLyte Capital LLC, or, if you have further questions, fill out the subscription documents and text me at 301-412-8622 or email marjorie6116@gmail.com TODAY with your investment amount — first come, first served —we only have $500,000 left in the SPV!

Yours truly- Toby

Last Chance to Lock-In 10X-20X $Cash-on-$Cash Return from the Medtech Investment of the Decade with ZERO Daily Stock Market VOLATILITY!